A detailed history of Charles Schwab Investment Management Inc transactions in Savara Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 911,617 shares of SVRA stock, worth $2.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
911,617
Previous 269,358 238.44%
Holding current value
$2.92 Million
Previous $1.09 Million 256.22%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.96 - $5.07 $2.54 Million - $3.26 Million
642,259 Added 238.44%
911,617 $3.87 Million
Q2 2024

Aug 12, 2024

BUY
$3.66 - $5.34 $98,025 - $143,021
26,783 Added 11.04%
269,358 $1.09 Million
Q1 2024

May 08, 2024

SELL
$4.19 - $5.59 $25,085 - $33,467
-5,987 Reduced 2.41%
242,575 $1.21 Million
Q3 2023

Nov 08, 2023

BUY
$2.97 - $3.88 $101,609 - $132,742
34,212 Added 15.96%
248,562 $939,000
Q2 2023

Aug 09, 2023

BUY
$1.69 - $3.24 $315,710 - $605,267
186,811 Added 678.35%
214,350 $683,000
Q1 2023

May 11, 2023

SELL
$1.6 - $2.82 $24,548 - $43,267
-15,343 Reduced 35.78%
27,539 $53,000
Q2 2021

Aug 16, 2021

SELL
$1.51 - $2.29 $86,331 - $130,926
-57,173 Reduced 57.14%
42,882 $73,000
Q1 2021

May 17, 2021

SELL
$1.17 - $2.33 $10,179 - $20,271
-8,700 Reduced 8.0%
100,055 $209,000
Q2 2020

Aug 14, 2020

BUY
$1.8 - $3.05 $52,772 - $89,419
29,318 Added 36.91%
108,755 $271,000
Q1 2020

May 15, 2020

BUY
$1.91 - $4.08 $2,708 - $5,785
1,418 Added 1.82%
79,437 $169,000
Q2 2019

Aug 09, 2019

BUY
$2.37 - $11.7 $44,337 - $218,883
18,708 Added 31.54%
78,019 $185,000
Q1 2019

May 14, 2019

SELL
$6.71 - $8.6 $13,332 - $17,088
-1,987 Reduced 3.24%
59,311 $438,000
Q3 2018

Nov 13, 2018

BUY
$10.49 - $12.87 $80,143 - $98,326
7,640 Added 14.24%
61,298 $685,000
Q2 2018

Aug 08, 2018

BUY
$8.55 - $13.76 $458,775 - $738,334
53,658 New
53,658 $608,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.